false
0001757499
0001757499
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 13, 2026
SHUTTLE
PHARMACEUTICALS HOLDINGS, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41488 |
|
82-5089826 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
401
Professional Drive, Suite 260
Gaithersburg,
MD 20879
(Address
of principal executive offices) (Zip Code)
(240)
430-4212
(Registrant’s
telephone number, including area code)
N/A
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock $0.00001 per
share |
|
SHPH |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01 Entry Into A Material Definitive Agreement.
On
November 13, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) entered into an Amendment to Securities Purchase
Agreement (the “SPA Amendment”) with certain investors constituting at least 67% of the purchasers under the Securities Purchase
Agreement, dated as of April 30, 2026 (the “Securities Purchase Agreement”), pursuant to which the Company issued (i) 1,910
shares of Series B-2 convertible preferred stock, par value $0.00001 per share, and (ii) common stock purchase warrants, in a private
placement that closed on May 6, 2026 (the “PIPE Financing”). Capitalized terms used but not defined herein have the meanings
given to them in the Securities Purchase Agreement.
Registration
Statement Deadlines. The SPA Amendment amends and restates Section 4.12 of the Securities Purchase Agreement to require the Company
to file registration statements covering the resale of the following securities, each of which must be declared effective by the Securities
and Exchange Commission (the “SEC”) by the tenth Business Day following its filing date (or by the 90th day following its
filing date if the SEC reviews the registration statement), not be withdrawn and not be subject to a stop order: (i) on or before January
31, 2027, the Conversion Shares and the Warrant Shares; (ii) on or before March 1, 2027, one-third of the Milestone Shares; (iii) on
or before April 1, 2027, an additional one-third of the Milestone Shares; and (iv) on or before May 1, 2027, the remaining one-third
of the Milestone Shares. The Company is also required to ensure that the prospectus contained in each such registration statement complies
with the applicable prospectus requirements.
Milestone
Event. The SPA Amendment amends the definition of “Milestone Event” in Section 2.4(b) of the Securities Purchase Agreement
by (i) reducing the number of Mining Rigs from 2,000 to 500 and (ii) amending and restating clause (ii) of such definition to provide
for the earlier of (A) February 1, 2027 and (B) the date on which the Company or a subsidiary achieves a minimum 90% fleet operational
uptime (the “Minimum Uptime”) and maintains the Minimum Uptime for any seven consecutive day period, excluding scheduled
maintenance windows and force majeure events, provided that such date is on or prior to the 60th calendar day anniversary of the commencement
of operational uptime of the Mining Rigs. The SPA Amendment amends only the conditions for satisfying the Milestone Event and does not
change the maximum number of Milestone Shares issuable upon satisfaction of the Milestone Event. The SPA Amendment conforms the Milestone
Event threshold in the Securities Purchase Agreement to the reduced Mining Rig threshold previously effected under the Agreement and
Plan of Merger, dated April 30, 2026, among the Company, United Dogecoin Inc. (“UDC”) and Shuttle Merger Sub, Inc. (as amended
by the First Amendment to Merger Agreement, dated August 31, 2026, the “Merger Agreement”).
Except
as expressly set forth in the SPA Amendment, the terms of the Securities Purchase Agreement remain in full force and effect. The foregoing
description of the SPA Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the
SPA Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
3.02 Unregistered Sales of Equity Securities.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.
On
November 13, 2026, following the effectiveness of the SPA Amendment and the Company’s determination that the applicable Milestone
Events under the Securities Purchase Agreement and the Merger Agreement had been satisfied, the Company issued pre-funded warrants (the
“Milestone Pre-Funded Warrants”) to purchase up to an aggregate of 6,693,740 shares of the Company’s common stock,
par value $0.001 per share (the “Common Stock”), consisting of: (a) pre-funded warrants issued to the Purchasers party to
the Securities Purchase Agreement, as amended by the SPA Amendment (the “SPA Milestone Pre-Funded Warrants”), to purchase
up to an aggregate of 2,099,142 shares of Common Stock; (b) pre-funded warrants issued to the former stockholders of UDC pursuant to
the Merger Agreement (the “UDC Milestone Pre-Funded Warrants”) to purchase up to an aggregate of 4,097,584 shares of Common
Stock; and (c) pre-funded warrants issued to EF Hutton (“EF Hutton”), and one other recipient pursuant to the Merger Agreement
(the “Additional Milestone Pre-Funded Warrants”) to purchase up to an aggregate of 497,014 shares of Common Stock. The Milestone
Pre-Funded Warrants were issued under the Securities Purchase Agreement and the Merger Agreement, as applicable, and the Company received
no additional cash consideration for their issuance. The Milestone Pre-Funded Warrants have an exercise price of $0.001 per share, are
exercisable immediately upon issuance and remain exercisable until exercised in full. A holder may not exercise any portion of a Milestone
Pre-Funded Warrant to the extent that, after giving effect to such exercise, the holder (together with its affiliates) would beneficially
own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding Common Stock immediately after giving effect to such
exercise.
The
Milestone Pre-Funded Warrants were issued, and the shares of Common Stock issuable upon exercise thereof will be issued, in reliance
on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”),
and, with respect to any cashless exercise, Section 3(a)(9) of the Securities Act, as transactions by an issuer not involving a public
offering. Each Purchaser represented in the Securities Purchase Agreement, and each former stockholder of UDC and each other recipient
of Milestone Pre-Funded Warrants represented in the Merger Agreement or related documentation, that it is an “accredited investor”
as defined in Rule 501(a) of Regulation D and that it acquired the securities for investment purposes only and not with a view to distribution
in violation of the Securities Act. Neither the Milestone Pre-Funded Warrants nor the shares of Common Stock issuable upon exercise thereof
have been registered under the Securities Act or any state securities laws, and they may not be offered or sold in the United States
absent registration or an applicable exemption from registration requirements.
Item
8.01 Other Events.
The
Company has determined that each of the three Milestone Events giving rise to the issuance of pre-funded warrants under the Securities
Purchase Agreement and the Merger Agreement and related agreements has been satisfied. As a result, as of November 13, 2026, the Company
had issued pre-funded warrants to purchase an aggregate of (a) 3,148,713 shares of Common Stock to the Purchasers pursuant to the Securities
Purchase Agreement (including the SPA Milestone Pre-Funded Warrants), (b) 12,292,751 shares of Common Stock to the former stockholders
of UDC pursuant to the Merger Agreement (including the UDC Milestone Pre-Funded Warrants) and (c) 1,491,042 shares of Common Stock to
EF Hutton and one other recipient pursuant to the Merger Agreement (including the Additional Milestone Pre-Funded Warrants).
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
| Exhibit
No. |
|
Description |
| 10.1 |
|
Form of Amendment to Securities Purchase Agreement, dated as of November 13, 2026, by and among Shuttle Pharmaceuticals Holdings, Inc. and the purchasers party thereto |
| 104 |
|
Cover
Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SHUTTLE PHARMACEUTICALS
HOLDINGS, INC. |
| Dated: November 19, 2026 |
|
|
| |
By: |
/s/
Chris Cooper |
| |
Name: |
Chris Cooper |
| |
Title: |
Co-Chief Executive Officer |